TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search results
By securing the WHO’s elite global benchmark, Indonesia has transformed regulatory trust from a technical achievement into a strategic asset, proving that middle-income nations can lead the world in global health security.
Rather than cutting vaccine funding, governments should be looking at increasing funds to provide vaccines to the world's most vulnerable children, saving half a million lives and delivering millions in additional social benefits each year.
The Bill & Melinda Gates Foundation has renewed its long-standing partnership with Indonesia following a high-profile visit by Bill Gates to Jakarta in early May. While the Foundation emphasized its commitment to improving public health and healthcare access in the country, one initiative in particular—trials for a novel tuberculosis (TB) vaccine—has attracted growing public skepticism and concern.
Some Indonesian netizens oppose the clinical trial of a tuberculosis (TB) vaccine candidate in Indonesia, whose development has been supported by the Gates Foundation. They claim that the state is selling people as "lab rats" for the philanthropist’s agenda.
The government has scaled up efforts against tuberculosis by empowering local communities and strengthening health facilities down to the village and subdistrict levels for the early detection and treatment of the world’s deadliest infectious disease.
